The insurer is waiting to hear more information from CMS before moving to cover the drug, according to WPRI.
Blue Cross Blue Shield of Rhode Island is the latest Blue Cross Blue Shield affiliate to announce it won’t be covering Aduhelm.
“After review by a local, independent panel of healthcare providers to assess the health and safety of [Aduhelm], Blue Cross & Blue Shield of Rhode Island has designated [Aduhelm] non-covered based on an evaluation of safety and clinical efficacy for non-Medicare members,” a Blue Cross Blue Shield of Rhode Island spokesperson told WPRI.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.